FORM 51-102F3
MATERIAL CHANGE REPORT

ITEM 1 – NAME AND ADDRESS OF COMPANY

Mind Cure Health Inc. (the "**Company**")
422 Richards Street, Suite 170
Vancouver, BC V6B 1B3

ITEM 2 – DATES OF MATERIAL CHANGE

March 16, 2022

ITEM 3 – NEWS RELEASES

News release announcing the material change was disseminated by the Company on March 16, 2022 through the newswire services of Cision.

ITEM 4 – SUMMARY OF MATERIAL CHANGE

The Company announced on March 16, 2022 that a special committee (the "**Special Committee**") of its board of directors (the "**Board**") had completed an extensive canvas of various strategic alternatives available to the Company, and determined that the additional capital required to execute the Company's business plan is unlikely to be found under the current and foreseeable market conditions and that none of the strategic alternatives available to the Company necessitated ongoing developmental expenditures. Accordingly, the Board made the decision to immediately eliminate all expenditures outside those required to preserve the value of the Company's existing assets.

On March 16, 2022 the Company initiated a Company-wide workforce reduction with respect to all of its C-suite executives and employees, other than its Chief Financial Officer, Vice President of Engineering and certain administrative staff required to wind-down the Company's operations and for limited care and maintenance of the Company; and halt all non-committed expenditures related to the development and marketing work of its iSTRYM product, the research and development related to its synthetic ibogaine program, and the research and development related to its Desire Project. Mr. Philip Tapley, the Chair of the Board, assumed the role of the Company's interim CEO.

ITEM 5.1 – FULL DESCRIPTION OF MATERIAL CHANGE

The Company announced on March 16, 2022 that its Special Committee had completed an extensive canvas of various strategic alternatives available to the Company, and determined that the additional capital required to execute the Company's business plan is unlikely to be found under the current and foreseeable market conditions and that none of the strategic alternatives available to the Company necessitated ongoing developmental expenditures. Accordingly, the Board made the decision to immediately eliminate all expenditures outside those required to preserve the value of the Company's existing assets.

On March 16, 2022 the Company initiated a Company-wide workforce reduction with respect to all of its C-suite executives and employees, other than its Chief Financial Officer, Vice President of Engineering and certain administrative staff required to wind-down the Company's operations and for limited care and maintenance of the Company; and halt all non-committed expenditures related to the development and marketing work of its iSTRYM product, the research and development related to its synthetic ibogaine program, and the research and development related to its Desire Project. Mr. Philip Tapley, the Chair of the Board, assumed the role of the Company's interim CEO.

The current Board and officers of the Company are now as follows:

Name	Position with the Company
Philip Tapley	Interim CEO, Chair of the Board and Director
Michael Wolfe	Chief Financial Officer
Robert Hill	Corporate Secretary and Director
Jason Pamer	Director
Larissa Chaikowsky	Director

ITEM 5.2 – DISCLOSURE FOR RESTRUCTURING TRANSACTIONS

Not applicable.

ITEM 6 – RELIANCE ON SUBSECTION 7.1(2) OF NATIONAL INSTRUMENT 51-102

Not applicable.

ITEM 7 – OMITTED INFORMATION

Not applicable.

ITEM 8 – EXECUTIVE OFFICER

The following executive officer of the Company is knowledgeable about the material change and this Report:

Philip Tapley, Interim Chief Executive Officer, Chair of the Board
Mind Cure Health Inc.
Phone: 1-888-593-8995

ITEM 9 – DATE OF REPORT

March 17, 2022